Abivax slides as takeover chatter fades, prompting profit-taking in volatile biotech
Abivax’s U.S.-listed ADS (ABVX) fell about 6% as traders cooled on takeover speculation that had recently supported the stock. The latest catalyst remains M&A-related headlines and denials, leaving the shares vulnerable to profit-taking after a sharp run-up.
1) What’s moving the stock
Abivax SA’s American depositary shares (ABVX) traded lower in the latest session as the market backed away from the recent wave of takeover speculation that has driven big swings in the biotech’s price. With no confirmed deal announcement, the stock’s move looked driven more by sentiment shifts and positioning than by a fresh fundamental update.
2) The M&A narrative driving volatility
Over the past several weeks, Abivax has been repeatedly pulled around by acquisition headlines. A key recent flashpoint came March 12, 2026, when Abivax dismissed a French-media report suggesting AstraZeneca had an exclusive window to review confidential information ahead of a potential offer—an episode that underscored how rumor-driven the tape can be for ABVX.
3) Why downside can be sharp even without new fundamentals
ABVX has surged dramatically since last year’s positive Phase 3 ulcerative colitis induction data and the subsequent large financing, leaving the stock prone to fast pullbacks when deal chatter cools. The company also has an established at-the-market (ATM) program, which can add perceived supply overhang even when there is no confirmed disclosure of sales on a given day.